ArticleJournal of medicinal chemistry2026
Selective Nanobody-Derived Minibodies Targeting Galectin-1 and -7 Reveal Non-Redundant Glyco-Immune Functions and Therapeutic Potential in Triple-Negative Breast Cancer.
Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Galectins (GALs) act as glyco-immune checkpoints that modulate tumor immunity, but their overlapping expression complicates functional dissection and targeted inhibition. Here, we explore the distinct molecular and immunological roles of GAL-1 and GAL-7, two GAL sover expressed in triple-negative breast cancer (TNBC), and describe the development of highly selective nanobody-derived minibodies (G1M1 and G7M8) that specifically target each protein. In TNBC cells, GAL-1 and GAL-7 induced different cytokine profiles: GAL-1 increased pro-tumor mediators such as G-CSF and VEGF-A, while GAL-7 promoted immunomodulatory cytokines, highlighting their nonredundant functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.